PR
Public Relations
Home
PR
Media release
Therapex Presents Preclinical Study Results of Non-Small Cell Lung Cancer Drug at European Society for Medical Oncology
NOTICE
2023-10-10

 

 

  

Therapex, a subsidiary of Gradient, announced on October 10th that it will participate in the European Society for Medical Oncology (ESMO) 2023, where it will present the follow-up results from the preclinical study of its non-small cell lung cancer targeted anti-cancer drug, "TRX-221."

 

Earlier this year in April, Therapex revealed the preclinical study findings of TRX-221 at the American Association for Cancer Research (AACR) Meeting 2023. The study showcased the drug’s dose-dependent anti-cancer efficacy, as well as its ability to permeate the blood-brain barrier (BBB), in PDOX mouse models of Tagrisso-resistant lung cancer.

 

Therapex plans to share the follow-up results at the ESMO 2023 poster session, where it’ll include pharmacokinetics/pharmacodynamics (PK/PD) modeling data, as well as outcomes from various experiments demonstrating in vivo selectivity and brain permeability in wild-type mouse models of tumor transplantation.

 

CEO Koo Lee PhD stated, "I am pleased to announce the follow-up results of the preclinical study of TRX-221 at the world's top authority conference, following its presentation at AACR 2023." He added, "We will strive to expedite preparations for the first patient administration as soon as possible, given the recent FDA approval of the Investigational New Drug (IND) for the Phase 1 Clinical Trial."

 

ESMO is recognized as one of the world’s leading oncology references, drawing oncology experts and representatives from the biotech and pharmaceutical industries. This year's event will take place in Madrid, Spain from July 20 to July 24. 

 

 

Source: Korea Economic Magazine, Reporter Park In Hyuck (https://n.news.naver.com/mnews/article/015/0004900165?sid=105)

 

List